KR102693317B1 - 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체 - Google Patents

암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체 Download PDF

Info

Publication number
KR102693317B1
KR102693317B1 KR1020207029169A KR20207029169A KR102693317B1 KR 102693317 B1 KR102693317 B1 KR 102693317B1 KR 1020207029169 A KR1020207029169 A KR 1020207029169A KR 20207029169 A KR20207029169 A KR 20207029169A KR 102693317 B1 KR102693317 B1 KR 102693317B1
Authority
KR
South Korea
Prior art keywords
cancer
cells
cxcr4
ser
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207029169A
Other languages
English (en)
Korean (ko)
Other versions
KR20200132915A (ko
Inventor
마리아 벨라 쿠엔카
파블로 곤잘레즈 나바로
자이메 발렌틴 퀴로가
아델라 에스쿠데로 로페즈
루시아 페르난데즈 카사노바
안토니오 페레즈 마르티네즈
Original Assignee
푼다시온 파라 라 인베스티가시온 바이오메디카 델 호스피탈 우니베르시타리오 라 파즈
푼다시온 델 섹토르 푸블리코 에스타탈 센트로 나시오날 데 인베스티가시오네스 온콜로지카스 카를로스 3 (에프.에스.피 씨엔아이오)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 푼다시온 파라 라 인베스티가시온 바이오메디카 델 호스피탈 우니베르시타리오 라 파즈, 푼다시온 델 섹토르 푸블리코 에스타탈 센트로 나시오날 데 인베스티가시오네스 온콜로지카스 카를로스 3 (에프.에스.피 씨엔아이오) filed Critical 푼다시온 파라 라 인베스티가시온 바이오메디카 델 호스피탈 우니베르시타리오 라 파즈
Publication of KR20200132915A publication Critical patent/KR20200132915A/ko
Application granted granted Critical
Publication of KR102693317B1 publication Critical patent/KR102693317B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4219—Receptors for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020207029169A 2018-03-13 2019-03-13 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체 Active KR102693317B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642313P 2018-03-13 2018-03-13
US62/642,313 2018-03-13
PCT/IB2019/052042 WO2019175802A1 (en) 2018-03-13 2019-03-13 Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy

Publications (2)

Publication Number Publication Date
KR20200132915A KR20200132915A (ko) 2020-11-25
KR102693317B1 true KR102693317B1 (ko) 2024-08-07

Family

ID=66286540

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207029169A Active KR102693317B1 (ko) 2018-03-13 2019-03-13 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체

Country Status (7)

Country Link
US (1) US20230181635A1 (https=)
EP (1) EP3765519B1 (https=)
JP (2) JP7561631B2 (https=)
KR (1) KR102693317B1 (https=)
CN (1) CN112513079A (https=)
ES (1) ES2973728T3 (https=)
WO (1) WO2019175802A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN117715647A (zh) * 2021-04-08 2024-03-15 埃迪瓦生物治疗公司 用nk细胞和cd38靶向抗体治疗癌症
CN115836666B (zh) * 2021-09-20 2024-11-01 上海中医药大学附属龙华医院 原位骨肉瘤和肺转移瘤小鼠模型及其制法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525899A (ja) 2011-06-20 2014-10-02 ピエール、ファーブル、メディカマン エフェクター機能を有する抗ｃｘｃｒ４抗体および癌治療のためのその使用
WO2016201425A1 (en) 2015-06-12 2016-12-15 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
WO2017049228A1 (en) 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Modified natural killer cells having anti-fugetactic properties and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2532399T3 (es) 2003-03-05 2015-03-26 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
KR101722261B1 (ko) * 2006-10-02 2017-04-03 메다렉스, 엘.엘.시. Ｃｘｃｒ4에 결합하는 인간 항체 및 이의 용도
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
EA201071300A1 (ru) 2008-05-14 2011-06-30 Эли Лилли Энд Компани Антитела к cxcr4
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
US8877182B2 (en) * 2009-03-26 2014-11-04 Cellprotect Nordic Pharmaceuticals Ab Expansion of NK cells
WO2013013025A2 (en) 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
SG11201401386XA (en) 2011-11-09 2014-10-30 Bristol Myers Squibb Co Treatment of hematologic malignancies with an anti-cxcr4 antibody
PE20160671A1 (es) 2013-08-02 2016-07-09 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco
EP3066129B1 (en) 2013-11-06 2019-06-19 Bristol-Myers Squibb Company Treatment of c1013g/cxcr4-associated waldenström's macroglobulinemia with an anti-cxcr4 antibody
EP3212227B1 (en) * 2014-10-28 2020-01-15 Children's University Hospital Tübingen Treatment of pediatric bcp-all patients with an anti-kir antibody
US10813952B2 (en) * 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525899A (ja) 2011-06-20 2014-10-02 ピエール、ファーブル、メディカマン エフェクター機能を有する抗ｃｘｃｒ４抗体および癌治療のためのその使用
WO2016201425A1 (en) 2015-06-12 2016-12-15 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
WO2017049228A1 (en) 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Modified natural killer cells having anti-fugetactic properties and uses thereof

Also Published As

Publication number Publication date
KR20200132915A (ko) 2020-11-25
US20230181635A1 (en) 2023-06-15
EP3765519B1 (en) 2024-01-17
ES2973728T3 (es) 2024-06-24
CN112513079A (zh) 2021-03-16
JP2024105305A (ja) 2024-08-06
WO2019175802A9 (en) 2019-12-12
WO2019175802A1 (en) 2019-09-19
JP2021517588A (ja) 2021-07-26
JP7561631B2 (ja) 2024-10-04
EP3765519A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
JP7282401B2 (ja) 癌治療のための抗ｆａｍ１９ａ５抗体の用途
US20220324965A1 (en) Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP2021008487A (ja) 抗ｎｋｇ２ａ抗体を使用した治療計画
KR20210009308A (ko) 인간 넥틴4에 특이적인 항체
JP6649941B2 (ja) Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
AU2017228055A1 (en) Antibodies specific to human poliovirus receptor (PVR)
CN107405362A (zh) 抗dll3嵌合抗原受体及其使用方法
TWI845626B (zh) 增進治療癌症功效的il-4/il-13途徑抑制劑
JP2024105305A (ja) 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体
JP2020519579A (ja) Ｌｒｒｃ３３阻害剤およびその使用
US20240374644A1 (en) Herv-k antibody therapeutics
JP7148151B2 (ja) 抗レナラーゼ抗体および抗ｐｄ－１抗体を用いる、がんを処置するための組成物および方法
CN114008078A (zh) 具有增强的t细胞介导的对肿瘤细胞的细胞毒性作用的针对chi3l1和pd1的双特异性抗体
RU2836467C2 (ru) Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований
WO2026075950A1 (en) Dosing regimen for anti-dll3 agent
TW202224703A (zh) 治療癌症之方法、治療劑及用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201012

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220314

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240507

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240805

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240805

End annual number: 3

Start annual number: 1

PG1601 Publication of registration